|
Cardiology
A prospective, observational study of rivaroxaban for stroke prevention in atrial fibrillation: the XANAP Korea
Jaemin Shim, Young Keun On, Sun U. Kwon, Gi-Byoung Nam, Moon-Hyoung Lee, Hyung-Wook Park, Keun-Sik Hong, Nam-Ho Kim, Pierre Amarenco, Seung-Woon Rha, Dong-Gu Shin, Joung-Ho Rha, Young-Hoon Kim
Korean J Intern Med. 2021;36(4):906-913. Published online June 11, 2021
Background/Aims: Atrial fibrillation (AF)-related stroke accounts for 20% of ischemic strokes. Rivaroxaban use in AF patients for preventing stroke and systemic embolism was approved in 2013 in Korea. This study was to investigate the safety and effectiveness of rivaroxaban use in Korean patients wi..
|
|
|
A prospective survey of the persistence of warfarin or NOAC in nonvalvular atrial fibrillation: a COmparison study of Drugs for symptom control and complication prEvention of Atrial Fibrillation (CODE-AF)
Hyeongsoo Kim, Young Soo Lee, Tae-Hoon Kim, Myung-Jin Cha, Jung Myung Lee, Junbeom Park, Jin-Kyu Park, Ki-Woon Kang, Jaemin Shim, Jae-Sun Uhm, Hyung Wook Park, Eue-Keun Choi, Jin-Bae Kim, Changsoo Kim, Jun Kim, Boyoung Joung
Korean J Intern Med. 2020;35(1):99-108. Published online April 25, 2019
Background/Aims: Efforts to reduce stroke in patients with atrial fibrillation (AF) have focused on increasing physician adherence to oral anticoagulant (OAC) guidelines; however, the high early discontinuation rate of vitamin K antagonists (VKAs) is a limitation. Although non-VKA OACs (NOACs) are m..
|
|
|
Hemato-oncology
Long-term rivaroxaban for the treatment of acute venous thromboembolism in patients with active cancer in a prospective multicenter trial
Ho-Young Yhim, Won-Il Choi, Sung-Hyun Kim, Seung-Hyun Nam, Kyoung Ha Kim, Yeung-Chul Mun, Doyeun Oh, Hun-Gyu Hwang, Keun-Wook Lee, Eun-Kee Song, Yong Shik Kwon, Soo-Mee Bang
Korean J Intern Med. 2019;34(5):1125-1135. Published online May 23, 2018
Background/Aims: Limited data are available regarding the efficacy of rivaroxaban for the treatment of cancer-associated venous thromboembolism (VTE). The aim of this study was to evaluate the effectiveness and safety of rivaroxaban for the treatment of VTE in active cancer patients.
Methods: In th..
|
|
|
